COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes.
【저자키워드】 COVID-19, therapy, diabetes, 【초록키워드】 Inflammation, SARS-COV-2 infection, peptide, drug, inhibitors, type 2 diabetes, Dipeptidyl peptidase 4, Haemoglobin, COVID-19 infection, therapeutic, Patient, Effectiveness, RAAS, receptor, clinical care, disease, insulin, homeostasis, Glucose, Immune status, Activation, Effect, Medical doctor, recommendation, agonists, Course, include, provide, Potential, diabete, coexistent, 【제목키워드】 SARS-CoV-2, Type,